Marc Beer: Overseeing the Series B Funding for Treating Pelvic Floor Disorders in Women

Renovia was established to provide a broad range of products to diagnose and treat pelvic floor disorders in millions of women. The company was also formed to potentially better the lives of people through modern, innovative sensor technologies to create a digital health platform. The platform also allows precise and cost-effective treatment of weakened pelvic floor muscles. Renovia was founded to offer paramount solutions to these complications. The management is combining the growth of innovative FDA approved medical services coupled with the state-of-the-art patient based in order to gain control of their pelvic floor muscles. Renovia is also using patented technology, sensors as well as modern value-based care to reinforce compliance and adherence to treatment.


Headed by Marc Beer, the company recently received a Series B Funding after two years of its foundation. Mr. Beer closed on a $42 million funding. The round of financing will improve the company’s ability to expand its pipeline of drugs and biotechnology devices made for treating as well as diagnosing urinary incontinence in more than 100 million women. Mr. Beer has since joined his contributors from medtech firms to improve the existing products while developing the new ones. In the two years of its operation, Renovia has changed the manner in which common pelvic floor disorders are not only diagnosed but treated through therapies. The success of the firm rests in Marc Beer’s hands since he has tremendously transitioned the landscape by combining a series of experience as well as expertise and education. Renovia first completed Series A funding to lay a significant groundwork for the development of products that it needed to pursue. With his team, Beer became interested in the new technology that was developed to assist women to perform exercises in order to strengthen their pelvic floor muscles.


The recent Series B funding included $32.3 million and $10 million from venture debt dockets. The total is $42.3 million, and the leaders from Renovia intend for the funds to be used for the development as well as the testing of four additional therapeutic as well as diagnostic products such as Leva, a digital health system. The funding will additionally be channeled toward corporate development and future commercial launches. Learn more:

Regarding the raising of funds through a Series B round, Marc Beer noted that some of the funds would be spent in developing the next market generation of the Leva device. Information concerning the upgrades as well as the transformations that will be made to this device hasn’t been released, but they will undoubtedly apply to its improvement. Leva can be installed in the user’s mobile device. Marc Beer is a graduate of the Miami University situated in Ohio. He has a bachelor’s degree in science and has more than 20 years of experience in pharmaceuticals, devices as well as biotechnology.